Blood Res.  2020 Jul;55(S1):S58-S62. 10.5045/br.2020.S010.

Recent advances in the management of primary central nervous system lymphoma

• Choi YS

• KMID: 2504744
• DOI: http://doi.org/10.5045/br.2020.S010

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal lymphoma primarily involving the brain, spinal cord, or leptomeninges. PCNSL is associated with a relatively poor prognosis compared to other extranodal diffuse large B-cell lymphomas. However, methotrexate-based induction chemotherapy followed by consolidative chemotherapy or high-dose therapy and autologous stem cell transplantation has improved the survival outcome, together with reduced neurotoxicity. Recent studies found that aberrant activation of the B-cell receptor-signaling pathway and activation of the NF-B are frequent genetic alterations and could be good targets for the treatment of PCNSL. Herein, we have reviewed the current status and recent advances in the biology and management of PCNSL.

Keyword

Primary central nervous system lymphoma; Chemotherapy; Rituximab; Autologous stem cell transplantation; Ibrutinib

Reference

1. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. 2011; Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 105:1414–8. DOI: 10.1038/bjc.2011.357. PMID: 21915121. PMCID: PMC3241537.

2. O'Neill BP, Decker PA, Tieu C, Cerhan JR. 2013; The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma. Am J Hematol. 88:997–1000. DOI: 10.1002/ajh.23551. PMID: 23873804. PMCID: PMC4020348.

3. Mendez JS, Ostrom QT, Gittleman H, et al. 2018; The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 20:687–94. DOI: 10.1093/neuonc/nox187. PMID: 29036697. PMCID: PMC5892148.

4. Bataille B, Delwail V, Menet E, et al. 2000; Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 92:261–6. DOI: 10.3171/jns.2000.92.2.0261. PMID: 10659013.

5. Hong JT, Chae JB, Lee JY, Kim JG, Yoon YH. 2011; Ocular involvement in patients with primary CNS lymphoma. J Neurooncol. 102:139–45. DOI: 10.1007/s11060-010-0303-9. PMID: 20658258.

6. Coulon A, Lafitte F, Hoang-Xuan K, et al. 2002; Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol. 12:329–40. DOI: 10.1007/s003300101037. PMID: 11870430.

7. Abrey LE, Batchelor TT, Ferreri AJ, et al. 2005; Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 23:5034–43. DOI: 10.1200/JCO.2005.13.524. PMID: 15955902.

8. Weller M. 1999; Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol. 43:237–9. DOI: 10.1023/A:1006254518848. PMID: 10563429.

9. Ferreri AJ, Blay JY, Reni M, et al. 2003; Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 21:266–72. DOI: 10.1200/JCO.2003.09.139. PMID: 12525518.

10. Abrey LE, Ben-Porat L, Panageas KS, et al. 2006; Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 24:5711–5. DOI: 10.1200/JCO.2006.08.2941. PMID: 17116938.

11. Jahnke K, Thiel E, Martus P, et al. 2006; Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 80:159–65. DOI: 10.1007/s11060-006-9165-6. PMID: 16699873.

12. Reni M, Ferreri AJ, Villa E. 1999; Second-line treatment for primary central nervous system lymphoma. Br J Cancer. 79:530–4. DOI: 10.1038/sj.bjc.6690083. PMID: 10027325. PMCID: PMC2362452.

13. Nayak L, Hedvat C, Rosenblum MK, Abrey LE, DeAngelis LM. 2011; Late relapse in primary central nervous system lymphoma: clonal persistence. Neuro Oncol. 13:525–9. DOI: 10.1093/neuonc/nor014. PMID: 21372070. PMCID: PMC3093334.

14. Vater I, Montesinos-Rongen M, Schlesner M, et al. 2015; The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia. 29:677–85. DOI: 10.1038/leu.2014.264. PMID: 25189415.

15. Braggio E, McPhail ER, Macon W, et al. 2011; Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. Clin Cancer Res. 17:4245–53. DOI: 10.1158/1078-0432.CCR-11-0395. PMID: 21562036. PMCID: PMC3131452.

16. Davis RE, Ngo VN, Lenz G, et al. 2010; Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 463:88–92. DOI: 10.1038/nature08638. PMID: 20054396. PMCID: PMC2845535.

17. Bellinzona M, Roser F, Ostertag H, Gaab RM, Saini M. 2005; Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol. 31:100–5. DOI: 10.1016/j.ejso.2004.10.002. PMID: 15642434.

18. Nelson DF, Martz KL, Bonner H, et al. 1992; Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 23:9–17. DOI: 10.1016/0360-3016(92)90538-S.

19. Glantz MJ, Cole BF, Recht L, et al. 1998; High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 16:1561–7. DOI: 10.1200/JCO.1998.16.4.1561. PMID: 9552066.

20. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Radiation Therapy Oncology Group Study 93-10. 2002; Combination chemotherapy and radiotherapy for primary central nervous system lymphoma:. J Clin Oncol. 20:4643–8. DOI: 10.1200/JCO.2002.11.013. PMID: 12488408.

21. Ferreri AJ, Reni M, Foppoli M, et al. 2009; High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 374:1512–20. DOI: 10.1016/S0140-6736(09)61416-1. PMID: 19767089.

22. Ferreri AJ, Cwynarski K, Pulczynski E, et al. 2016; Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 3:e217–27. DOI: 10.1016/S2352-3026(16)00036-3.

23. Morris PG, Correa DD, Yahalom J, et al. 2013; Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 31:3971–9. DOI: 10.1200/JCO.2013.50.4910. PMID: 24101038. PMCID: PMC5569679.

24. Doolittle ND, Korfel A, Lubow MA, et al. 2013; Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology. 81:84–92. DOI: 10.1212/WNL.0b013e318297eeba. PMID: 23685932. PMCID: PMC3770201.

25. Juergens A, Pels H, Rogowski S, et al. 2010; Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol. 67:182–9. DOI: 10.1002/ana.21824. PMID: 20225195.

26. Thiel E, Korfel A, Martus P, et al. 2010; High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 11:1036–47. DOI: 10.1016/S1470-2045(10)70229-1. PMID: 20970380.

27. Ferreri AJ, Guerra E, Regazzi M, et al. 2004; Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer. 90:353–8. DOI: 10.1038/sj.bjc.6601472. PMID: 14735176. PMCID: PMC2409565.

28. Batchelor T, Carson K, O'Neill A, et al. 2003; Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 21:1044–9. DOI: 10.1200/JCO.2003.03.036. PMID: 12637469.

29. Bromberg JEC, Issa S, Bakunina K, et al. 2019; Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 20:216–28. DOI: 10.1016/S1470-2045(18)30747-2. PMID: 30630772.

30. Khan RB, Shi W, Thaler HT, DeAngelis LM, Abrey LE. 2002; Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol. 58:175–8. DOI: 10.1023/A:1016077907952. PMID: 12164690.

31. Sierra Del Rio M, Ricard D, Houillier C, et al. 2012; Prophylactic intrathecal chemotherapy in primary CNS lymphoma. J Neurooncol. 106:143–6. DOI: 10.1007/s11060-011-0649-7. PMID: 21739169.

32. Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. 2011; Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 76:929–30. DOI: 10.1212/WNL.0b013e31820f2d94. PMID: 21383331. PMCID: PMC3059144.

33. Ferreri AJM, Cwynarski K, Pulczynski E, et al. 2017; Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 4:e510–23. DOI: 10.1016/S2352-3026(17)30174-6.

34. Choquet S, Houillier C, Bijou F, et al. 2016; Ibrutinib monotherapy in relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreo-retinal lymphoma (PVRL). Result of the interim analysis of the iLOC phase II study from the Lysa and the French LOC Network. Blood (ASH Annual Meeting Abstracts). 128(Suppl):784. DOI: 10.1182/blood.V128.22.784.784.

35. Grommes C, Pastore A, Palaskas N, et al. 2017; Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 7:1018–29. DOI: 10.1158/2159-8290.CD-17-0613. PMID: 28619981. PMCID: PMC5581705.

36. Lionakis MS, Dunleavy K, Roschewski M, et al. 2017; Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 31:833–43. DOI: 10.1016/j.ccell.2017.04.012. PMID: 28552327. PMCID: PMC5571650.

37. Dredge K, Horsfall R, Robinson SP, et al. 2005; Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 69:56–63. DOI: 10.1016/j.mvr.2005.01.002. PMID: 15797261.

38. Tun HW, Johnston PB, Grommes C, et al. 2017; Phase I clinical trial on pomalidomide and dexamethasone in treating patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) or primary vitreoretinal lymphoma (PVRL). J Clin Oncol (ASCO Annual Meeting Abstracts). 35(Suppl):abst 7516. DOI: 10.1200/JCO.2017.35.15_suppl.7516.

39. Ghesquieres H, Chevrier M, Laadhari M, et al. 2019; Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral Lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). Ann Oncol. 30:621–8. DOI: 10.1093/annonc/mdz032. PMID: 30698644.

40. Nayak L, Iwamoto FM, LaCasce A, et al. 2017; PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 129:3071–3. DOI: 10.1182/blood-2017-01-764209. PMID: 28356247. PMCID: PMC5766844.

41. Chapuy B, Roemer MG, Stewart C, et al. 2016; Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 127:869–81. DOI: 10.1182/blood-2015-10-673236. PMID: 26702065. PMCID: PMC4760091.

42. Grommes C, Tang SS, Wolfe J, et al. 2019; Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 133:436–45. DOI: 10.1182/blood-2018-09-875732. PMID: 30567753. PMCID: PMC6356986.